Edwards Pulls Some Lots of Sapien M3 Delivery System: FDA Alert

Three TMVR cases have seen balloons burst during inflation, with one death and one serious injury related to the issue.

Edwards Pulls Some Lots of Sapien M3 Delivery System: FDA Alert

Edwards Lifesciences has pulled certain lots of the delivery system used for Sapien M3 transcatheter mitral valve replacement (TMVR) after receiving three reports of balloons bursting during inflation, according to a US Food and Drug Administration “early alert” released Thursday.

According to the alert, Edwards sent a letter to customers informing them to search their inventory and remove Commander M delivery systems with the following lot numbers: 67718561, 67804014, 67887043, and 67887044.

“Potential injuries associated with balloon burst include embolism and inability to retrieve the device through the guide sheath, which may require additional intervention, including surgery,” the FDA explained. “Because this patient population is deemed unsuitable for surgery, these interventions carry a high risk of serious adverse health consequences including death.”

The issue has been associated with one death and one serious injury as of October 5, according to the company.

The FDA said that it is “currently reviewing information about this potentially high-risk device issue and will keep the public informed as significant new information becomes available.”

Sapien M3, a fully percutaneous TMVR system with transseptal delivery, was approved by the FDA in December 2025 for the treatment of patients with symptomatic moderate-to-severe mitral regurgitation or symptomatic mitral valve dysfunction associated with mitral annular calcification who are deemed unsuitable for surgery or transcatheter edge-to-edge repair. That decision was supported by the results of the single-arm ENCIRCLE trial.

Sources

Comments